EGFR and non-small cell lung carcinoma: Osimertinib (6), icotinib (7), gefitinib (8) and erlotinib (9) as adjuvant targeted treatments showed better disease-free survival (DFS) benefits than chemotherapy (30.8-47.0 vs. 19.8-22.1 months) for patients with NSCLC with epidermal growth factor receptor (EGFR) mutations.